pharmaphorum December 24, 2025
In the latest of a flurry of announcements ahead of the holiday period, CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity through Medicare and Medicaid.
The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) scheme will allow Medicare Part D plans and state Medicaid agencies to cover GLP-1 drugs, after negotiating prices with the federal government.
The announcement comes a few weeks after the Trump administration announced price discounts to $149 per month for GLP-1-acting drugs provided through Medicare and Medicaid, as well as for cash purchasers. That agreement covered Novo Nordisk’s semaglutide products for diabetes (Ozempic) and weight loss (Wegovy), along with Eli...
Today's Sponsors
Today's Sponsor